Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. INVA
stocks logo

INVA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
91.30M
+2.01%
--
--
101.53M
+10.59%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Innoviva, Inc. (INVA) for FY2025, with the revenue forecasts being adjusted by 4.87% over the past three months. During the same period, the stock price has changed by 1.56%.
Revenue Estimates for FY2025
Revise Upward
up Image
+4.87%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+31.46%
In Past 3 Month
Stock Price
Go Up
up Image
+1.56%
In Past 3 Month
Wall Street analysts forecast INVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INVA is 32.00 USD with a low forecast of 17.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast INVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INVA is 32.00 USD with a low forecast of 17.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
1 Sell
Moderate Buy
Current: 20.800
sliders
Low
17.00
Averages
32.00
High
45.00
Current: 20.800
sliders
Low
17.00
Averages
32.00
High
45.00
Goldman Sachs
Sell
initiated
$17
2025-09-30
Reason
Goldman Sachs
Price Target
$17
2025-09-30
initiated
Sell
Reason
Goldman Sachs initiated coverage of Innoviva with a Sell rating and $17 price target. The stock's recent rally has raised the bar for the company's infectious disease platform platform going forward, the analyst tells investors in a research note. The firm believes Innoviva's 2031 royalty-related patent cliff will start to weigh on the stock's performance in 2026.
H.C. Wainwright
Raghuram Selvaraju
Buy
upgrade
$40 -> $45
2025-08-11
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$40 -> $45
2025-08-11
upgrade
Buy
Reason
H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Innoviva to $45 from $40 and keeps a Buy rating on the shares. The company's Q2 revenue and earnings outperformed expectations, the analyst tells investors in a research note.
Oppenheimer
Outperform
initiated
$35
2025-08-11
Reason
Oppenheimer
Price Target
$35
2025-08-11
initiated
Outperform
Reason
Oppenheimer initiated coverage of Innoviva with an Outperform rating and $35 price target. Innoviva is a holding company comprised of royalty distributions from Breo and Anoro, a specialty therapeutics unit with assets for treating acute critical care, and a strategic finance equity investments arm, the analyst tells investors in a research note. The firm believes the company's specialty therapeutics and royalty commercial results will drive share outperformance.
H.C. Wainwright
H.C. Wainwright
initiated
$40
2025-07-14
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$40
2025-07-14
initiated
Reason
H.C. Wainwright initiated coverage of Innoviva with a Buy rating and $40 price target. The firm says Innoviva is a diversified company marketing multiple commercial products that is benefiting from "durable" royalty streams on mass market respiratory disease franchises.
Cantor Fitzgerald
NULL -> Overweight
initiated
$26
2025-07-11
Reason
Cantor Fitzgerald
Price Target
$26
2025-07-11
initiated
NULL -> Overweight
Reason
Cantor Fitzgerald initiated coverage of Innoviva with an Overweight rating and $26 price target.
Scotiabank
Louise Chen
Buy
Initiates
$55
2025-03-07
Reason
Scotiabank
Louise Chen
Price Target
$55
2025-03-07
Initiates
Buy
Reason
Scotiabank initiated coverage of Innoviva with an Outperform rating and $55 price target. Innoviva's stock has been overlooked because its value proposition is not explicitly clear, but bolder moves to maximize shareholder value could be coming, including new launches, expanding the Innoviva Specialty Therapeutics platform, and monetizing non-core assets, the analyst tells investors in a research note. The stock also looks interesting in a tough capital markets environment because it is profitable and has historically been successful at consolidating undervalued assets, the firm argues.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Innoviva Inc (INVA.O) is 10.06, compared to its 5-year average forward P/E of 11.75. For a more detailed relative valuation and DCF analysis to assess Innoviva Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
11.75
Current PE
10.06
Overvalued PE
17.87
Undervalued PE
5.63

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
7.19
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
9.79
Undervalued EV/EBITDA
4.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.45
Current PS
0.00
Overvalued PS
4.20
Undervalued PS
2.69
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

INVA News & Events

Events Timeline

(ET)
2025-11-05
16:32:30
Innoviva Board Approves $125 Million Stock Buyback Plan
select
2025-11-05
16:32:05
Innoviva announces Q3 earnings per share of $1.08 compared to 2 cents in the same period last year.
select
2025-06-12 (ET)
2025-06-12
07:18:48
Innoviva announces zoliflodacin NDA granted Priority Review by FDA
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-27NASDAQ.COM
Biotech Stocks Await FDA Verdict in December 2025

  • National Influenza Vaccination Week: Observed from December 1-5, this campaign encourages vaccination against the flu, emphasizing its safety and effectiveness, and serves as a reminder that it's never too late to get vaccinated.

  • World AIDS Day: Celebrated on December 1, this global observance raises awareness about HIV/AIDS, honors those lost, and supports those living with the virus, with a focus on political leadership and human rights to end AIDS as a public health threat by 2030.

  • HIV Statistics: In 2024, approximately 40.8 million people were living with HIV, with around 630,000 deaths from HIV-related causes and 1.3 million new infections, highlighting the ongoing impact of the epidemic.

  • Funding Concerns: There are worries about significant cuts to international HIV funding, particularly from the U.S., which has historically contributed nearly 75% of global financing, with recent reductions affecting key commitments and activities related to World AIDS Day.

[object Object]
Preview
4.0
11-06Benzinga
Cantor Fitzgerald Keeps Overweight Rating on Innoviva, Increases Price Target to $31

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.

[object Object]
Preview
9.5
11-06NASDAQ.COM
Innoviva, Inc. Announces Rise in Q3 Earnings

  • Earnings Growth: Innoviva, Inc. reported a significant increase in earnings for the third quarter, totaling $89.91 million, or $1.08 per share, compared to $1.21 million, or $0.02 per share, from the previous year.

  • Revenue Increase: The company's revenue rose by 20.4% to $107.80 million, up from $89.51 million in the same quarter last year.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Innoviva Inc (INVA) stock price today?

The current price of INVA is 20.8 USD — it has decreased -0.29 % in the last trading day.

arrow icon

What is Innoviva Inc (INVA)'s business?

Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.

arrow icon

What is the price predicton of INVA Stock?

Wall Street analysts forecast INVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INVA is 32.00 USD with a low forecast of 17.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Innoviva Inc (INVA)'s revenue for the last quarter?

Innoviva Inc revenue for the last quarter amounts to 107.80M USD, increased 20.44 % YoY.

arrow icon

What is Innoviva Inc (INVA)'s earnings per share (EPS) for the last quarter?

Innoviva Inc. EPS for the last quarter amounts to 1.06 USD, increased 5200.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Innoviva Inc (INVA)'s fundamentals?

The market is revising Upward the revenue expectations for Innoviva, Inc. (INVA) for FY2025, with the revenue forecasts being adjusted by 4.87% over the past three months. During the same period, the stock price has changed by 1.56%.
arrow icon

How many employees does Innoviva Inc (INVA). have?

Innoviva Inc (INVA) has 127 emplpoyees as of December 05 2025.

arrow icon

What is Innoviva Inc (INVA) market cap?

Today INVA has the market capitalization of 1.56B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free